{
Roche

People

}
001122334455554433221100
001122334455554433221100

Swiss stock market shows minimal movement amid mixed corporate earnings and monetary policy concerns

The Swiss stock market showed minimal movement, with the SMI down 0.07% to 8215.17 points and the SPI down 0.04% to 8908.21 points. Credit Suisse saw a surprising profit but fell 2.25%, while UBS and Julius Bär also declined. Defensive stocks like Nestlé and Roche had mixed results, and Logitech surged 7.83% in the broader market.
TicinoNews
Richemont DNS Inc. Julius Bär Stiftung Novartis AG Logitech SA Clariant AG Hoffmann-La Roche AG Swatch AG Credit Suisse Anlagestiftung Swiss Life AG Swiss Re AG Zurich Insurance Group AG ABB Ltd UBS AG LafargeHolcim Ltd. Nestlé S.A. BOBST MEX SA Basel Cantonal Bank Adecco Group AG CHE Swiss Re Novartis Roche Nestlé Bobst Zurich Logitech Julius Bär ABB LafargeHolcim Swatch Credit Suisse UBS Richemont Basel Cantonal Bank Adecco Swiss Life Clariant Show more
TradFi, Market Report
18:41 09.11.2024

Swiss stock exchange rallies as oil prices rise and key stocks gain

The Swiss stock exchange started the week positively, with the SMI Guiding Values Index rising 1.51% to 7982.44 points, while the SPI gained 1.50% to 8311.73 points. The market's optimism is fueled by increasing oil prices, benefiting companies like Transocean and cyclical stocks such as ABB and Adecco. Notable gains were also seen in banking and insurance sectors, with UBS and Swiss Re performing well, while EFG International faced a decline after announcing its acquisition of BSI.
TicinoNews
United States Dollar Julius Bär Stiftung Adecco Group AG Hoffmann-La Roche AG Nestlé S.A. LafargeHolcim Ltd. ABB Ltd Swiss Re AG Transocean Ltd. Novartis AG UBS AG Zurich Insurance Group AG EFG International AG Credit Suisse Anlagestiftung FRA CHE EFG International Novartis Adecco Transocean Nestlé ABB Julius Bär Swiss Re Roche Zurich UBS LafargeHolcim Credit Suisse Show more
TradFi, Market Report
20:10 08.11.2024

regeneron pharmaceuticals receives buy rating as it expands drug portfolio

Regeneron Pharmaceuticals, Inc. has received a buy rating from UBS, highlighting its focus on developing treatments for eye diseases, inflammatory conditions, and cancer. The company's net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. As of the end of 2022, Regeneron boasts a clinical development portfolio of approximately 35 products.
ch.marketscreener.com
United States Dollar Bayer AG Sanofi Hoffmann-La Roche AG Regeneron Pharmaceuticals, Inc. DEU FRA USA Roche Bayer Sanofi Show more
TradFi, Market Report
16:08 01.11.2024

Regeneron Pharmaceuticals receives buy rating amid strong sales and collaborations

Regeneron Pharmaceuticals, Inc. has received a buy rating from UBS, highlighting its focus on developing treatments for eye diseases, inflammatory conditions, and cancer. The company's net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. As of the end of 2022, Regeneron boasts a clinical development portfolio of approximately 35 products.
MarketScreener
United States Dollar Bayer AG Sanofi Hoffmann-La Roche AG Regeneron Pharmaceuticals, Inc. DEU FRA USA Roche Bayer Sanofi Show more
TradFi, Market Report
16:08 01.11.2024

Alnylam Pharmaceuticals reports mixed Q3 earnings amid rising product revenues

Alnylam Pharmaceuticals reported mixed Q3 earnings for the quarter ending September 30, 2024, with net product revenues rising to $420.1 million, up from $313.2 million the previous year. However, the company faced a net loss of $111.6 million, a decline from a net income of $147.8 million, primarily due to increased research and development expenses. Strategic collaborations with companies like Roche and Regeneron are expected to bolster future growth as Alnylam focuses on expanding its RNAi therapeutics pipeline.
TipRanks Financial
United States Dollar Hoffmann-La Roche AG Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. USA Roche Regeneron Pharmaceuticals Show more
Healthcare, Market Report
05:23 01.11.2024

global pharmaceutical and healthcare market projected to reach 1924 billion by 2032

Rising healthcare costs are straining patients, payers, and providers, limiting access to care and pressuring the pharmaceutical industry to maintain lower prices. The global pharmaceuticals and healthcare market is projected to grow from $1,245.88 billion in 2021 to $1,924.24 billion by 2032, driven by technological advances and demographic changes. However, regulatory barriers and increasing costs pose significant challenges to market growth.
businessresearchinsights.com
United States Dollar Hoffmann-La Roche AG Johnson & Johnson Novartis AG Merck & Co., Inc. AbbVie Inc. CAN FRA GBR USA ISR JPN DNK DEU Merck & Co Roche Johnson & Johnson AbbVie Novartis Show more
Healthcare, Market Report
09:00 07.10.2024
Trending
Subcategory
Corporate News Industry Trends Startups & Entrepreneurship Retail and Consumer Goods Supply Chain Management Global Trade Developments Stock Market Updates Government Economic Policies Industry Mergers & Acquisitions Energy Sector Developments Workplace Trends Funding Rounds & Investments CEO Changes AI Applications Private Equity Deals Emerging Startups Fintech Startups AI Innovations Global Financial Events Central Bank Actions
Countries:
USA CHN IND ARE SAU JPN GBR SGP KOR AUS IDN VNM HKG MYS DEU ISR CAN TWN TUR BGD
Companies:
Apple Inc. Google Inc. Tesla, Inc. Amazon.com, Inc. Microsoft Corporation Tesmec S.p.A. Alphabet Inc. OpenAI ERC USD Walmart Inc. SWIGGY LIMITED TENCENT NVIDIA Corporation Foxconn Technology Co., Ltd. Hollywood Bowl Group PLC NASDAQ Composite Wise plc Mastercard Inc Bose Corporation Mistral 1 Fast Retailing Co., Ltd.
Currencies:
United States Dollar Indian Rupee Chinese Yuan Euro Japanese Yen British Pound Sterling United Arab Emirates Dirham Vietnamese Đồng South Korean Won New Zealand Dollar Saudi Riyal Thai Baht Australian Dollar Indonesian Rupiah Singapore Dollar Omani Rial Bahraini Dinar Qatari Riyal Algerian Dinar Egyptian Pound
People:
Donald Trump Elon Musk Asmaa Naga Basma Bushnak Maha Taibah Ursula von der Leyen Hossam Ahmed Tasneem Islam Scott Bessent Joe Biden Sri Mulyani Mark Carney Howard Lutnick Yongqiang He Xi Jinping Aman Gupta Cristina Pitarch Mohamed Alkuwaiti Afeef Zaman Hareb Rashed

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.